Everfront Biotech Inc.

9 patents currently held · Updated Nov 14, 2026

Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Ending by 2030

Jul 2034

Next term end

When these terms end

5 yrs10 yrs20 yrs

Held patents by the year their term ends

20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.

1 fee due Apr 15, 2027
The maintenance fee for Use of Butylidenephthalide (US 10,441,566) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
1 fee due May 5, 2027
The maintenance fee for Method for Delaying the Onset of Pulmonary Fibrosis or Treating Pulmonary Fibrosis (US 10,463,645) comes due May 5, 2027. Unpaid by Nov 5, 2027, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

1 of the patents on this record was granted since Aug 16, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 9 of 9

Patent	Title	Status	Expires	Confidence
US 10,682,335	Use of butylidenephthalide (Bdph), method of using the same, and method for preparing pharmaceutical composition containing the same In force Term ends Jul 28, 2034 · From the USPTO record	In force	Term ends Jul 28, 2034	From the USPTO record
US 9,889,117	Method for Treating And/Or Delaying the Degeneration of Purkinje Cells In force Term ends Oct 1, 2034 · High confidence	In force	Term ends Oct 1, 2034	High confidence
US 9,504,751	Stable pharmaceutical composition In force Term ends Jun 20, 2035 · From the USPTO record	In force	Term ends Jun 20, 2035	From the USPTO record
US 9,884,835	Method for preparing isobenzofuran-1(3H)-one compound In force Term ends Oct 14, 2035 · From the USPTO record	In force	Term ends Oct 14, 2035	From the USPTO record
US 10,441,566	Use of Butylidenephthalide In force Term ends Jan 7, 2036 · High confidence	In force	Term ends Jan 7, 2036	High confidence
US 10,987,339	Uses of Butylidenephthalide In force Term ends Sep 9, 2036 · High confidence	In force	Term ends Sep 9, 2036	High confidence
US 10,463,645	Method for Delaying the Onset of Pulmonary Fibrosis or Treating Pulmonary Fibrosis In force Term ends May 22, 2037 · High confidence	In force	Term ends May 22, 2037	High confidence
US 10,688,128	Use of Z-Butylidenephthalide in Activating Autoimmune System In force Term ends Sep 17, 2037 · High confidence	In force	Term ends Sep 17, 2037	High confidence
US 12,740,964	Use of Phthalide Compounds in Treatment of Meningioma In force Term ends Aug 10, 2043 · High confidence	In force	Term ends Aug 10, 2043	High confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Export every term end as CSV · Pro

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 pending · 1 abandoned

List them